课题基金 / 基金详情

STUDIES IN GLAUCOMATOUS OPTIC NERVE DAMAGE

STUDIES IN GLAUCOMATOUS OPTIC NERVE DAMAGE
青光眼视神经损伤的研究
批准号:
6819742
负责人:
JOHN C MORRISON
金额:
$37.75万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-04-01 至 2006-02-28

项目摘要

项目成果

JOHN C MORRISON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Retinal ganglion cell (RGC) survival is thought to depend on the level of activation of TrkB receptors by the endogenous neurotrophins, BDNF and NT4/5. These neurotrophins (NT) are derived from the superior colliculus, and complex with specific TrkB receptors. They then travel by retrograde axonal transport to the RCG cell body. There they act to preserve RGC by stimulating specific cell survival pathways, and by inhibiting specific cell death pathways (apoptosis). Elevated intraocular pressure (IOP), a major risk factor for glaucoma, obstructs axonal transport, and has been shown to inhibit delivery of NT to the RGC. In addition, there is good reason to believe that other risk factors for glaucoma, such as aging and previous optic nerve damage, may also affect this system, possibly by reducing the production of TrkB receptors, the production of NT, or both. These facts lead to the hypothesis that, in glaucoma, RGC death results from a reduction in the activation of neurotrophin-dependent TrkB mediated survival pathways. Using Brown Norway rats, methods now exist for modeling chronically elevated IOP, surgically lowering IOP, and studying these phenomena in aged, as well as young adult animals. This proposal will determine the effects of these three important glaucoma risk factors on neurotrophin TrkB activated survival signaling pathways and on RGC survival. A final specific aim will pharmacologically enhance the activity of NT-mediated cell survival pathways in partially damaged eyes following IOP control. This models the most common clinical situation in glaucoma. Success will be gauged by measuring decreased RGC loss, as well as changes in NT-mediated signaling pathways that enhance survival. These experiments will help to determine the potential for agents that enhance TrkB-activation in RGCs as a neuroprotective therapy for glaucoma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mentored Vision Clinician-Scientist Program at OHSU
Mentored Vision Clinician-Scientist Program at OHSU
Ophthalmology Core Facility
Ophthalmology Core Facility
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
  • 批准号:
    31970691
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2019
  • 负责人:
    张胜萍
  • 依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
  • 批准号:
    31900527
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2019
  • 负责人:
    孙磊
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位: